Verenium (VRNM) and The Competition Head to Head Review

Verenium (NASDAQ: VRNM) is one of 33 public companies in the “Commodity Chemicals” industry, but how does it weigh in compared to its rivals? We will compare Verenium to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.

Institutional & Insider Ownership

70.9% of shares of all “Commodity Chemicals” companies are owned by institutional investors. 7.8% of shares of all “Commodity Chemicals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Verenium and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verenium 0 0 0 0 N/A
Verenium Competitors 107 835 1230 36 2.54

As a group, “Commodity Chemicals” companies have a potential upside of 1.86%. Given Verenium’s rivals higher probable upside, analysts clearly believe Verenium has less favorable growth aspects than its rivals.


This table compares Verenium and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verenium N/A N/A N/A
Verenium Competitors -29.50% 24.34% 5.63%

Risk and Volatility

Verenium has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Verenium’s rivals have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.

Earnings and Valuation

This table compares Verenium and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Verenium N/A N/A -2.56
Verenium Competitors $4.01 billion $340.26 million 131.15

Verenium’s rivals have higher revenue and earnings than Verenium. Verenium is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Verenium rivals beat Verenium on 7 of the 8 factors compared.

Verenium Company Profile

Verenium Corporation (Verenium) is an industrial biotechnology company. The Company develops and commercializes enzymes for use in a range of industrial processes. It manufactures and markets its enzyme products in the fields of animal health and nutrition, grain processing, oilfield services and other industrial processes, such as pulp and paper and textiles. As of December 31, 2012, it marketed commercial enzyme products, either independently or in collaboration with its partners. In addition, it has developed a pipeline of enzyme product candidates. Its products are organized into four product lines: animal health and nutrition, grain processing, oilfield services and other industrial processes. As of December 31, 2012, it markets nine commercial enzyme products. In October 2013, BASF SE acquired 71% stake in the Company.

Receive News & Ratings for Verenium Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verenium Corp and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply